In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Natural fragment Teriparatide (PTH 1-34) | Natural peptide Thymosin beta-4 (human) | |
|---|---|---|---|
| Identity | |||
| Kind | Natural fragment | Natural peptide | |
| Area | Recovery and repair | Recovery and repair | |
| Evidence | |||
| Amount of evidence | 2,709 | 1,449 (plus 953 on natural levels, listed separately) | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 209 (168 in people) | 12 (8 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 168 · 15 active30 more mention it but do not test it | 13 · 1 active2 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Forteo says: “The active N-terminal fragment of parathyroid hormone, approved for osteoporosis in selected patients”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Teriparatide (PTH 1-34) | Thymosin beta-4 (human) |
|---|---|---|
| Bone and jointPharmacology | 2,2281286913263 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 8 Oct 2026).
531142
| Adverse eventsWhole body | 16313726 | 981 |
|---|
| Receptor activity and mechanismPharmacology | 46151516 | 310292792 |
|---|
| PainMusculoskeletal | 6262 | 523 |
|---|
| PharmacokineticsPharmacology | 30273 | 287183 |
|---|
| NeuroprotectionNervous system and cognition | 11 | 1437964 |
|---|
| Wound healingSkin and wound | 11 | 12156650 |
|---|
| Kidney functionKidney and urinary | 27243 | 14131 |
|---|
| Immune responseImmune and inflammation | 321 | 861472 |
|---|
| Heart functionCardiovascular | 211 | 7225515 |
|---|
| Liver fat and liver functionLiver | 11 | 794237 |
|---|
| Exercise and physical functionMusculoskeletal | 1818 | 11 |
|---|
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Teriparatide (PTH 1-34) | Thymosin beta-4 (human) |
|---|---|---|
| PainEyeCompared as: difference from placebo, in % | −31% Relative risk reduction · Shown as a change. The study reports a relative risk reduction of this size. Dose studied: 20 microgmedian 19 monthsn = 1,0852005 | No comparable result 2 randomized-trial results measure it in another way or another unit. |
| Bone and jointMusculoskeletalCompared as: value in the arm that got the peptide, in % | 7.2% Lumbar spine BMD change Dose studied: 20 microg once daily18 monthsn = 4282007 | No randomized trial result |
| Exercise and physical functionMusculoskeletalCompared as: value in the arm that got the peptide, in s | −3.2 to −5.9 s TUG time difference versus risedronate · teriparatide minus risedronate, 6 to 26 weeks Dose studied: 20 μg every day78 weeksn = 1712017 | |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | 10% Nasopharyngitis Dose studied: 20 μg once daily12 monthsn = 4322017 | No comparable result 8 randomized-trial results measure it in another way or another unit. |
−31%
Relative risk reduction · Shown as a change. The study reports a relative risk reduction of this size.
Dose studied: 20 microgmedian 19 monthsn = 1,0852005
No comparable result
2 randomized-trial results measure it in another way or another unit.
53 results from other study designs.
No randomized trial result 1 result from other study designs. |
7.2%
Lumbar spine BMD change
Dose studied: 20 microg once daily18 monthsn = 4282007
No randomized trial result
53 results from other study designs.
−3.2 to −5.9 s
TUG time difference versus risedronate · teriparatide minus risedronate, 6 to 26 weeks
Dose studied: 20 μg every day78 weeksn = 1712017
No randomized trial result
1 result from other study designs.
10%
Nasopharyngitis
Dose studied: 20 μg once daily12 monthsn = 4322017
No comparable result
8 randomized-trial results measure it in another way or another unit.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 168 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Radius Health, Inc.2,463 participantsApr 2011 to Oct 2014
Osteoporosis · Postmenopausal Osteoporosis
Eli Lilly and Company1,366 participantsOct 2012 to Jul 2016
Postmenopausal Osteoporosis
Eli Lilly and Company712 participantsJun 2006 to Jun 2010
Osteoporosis, Postmenopausal · Back Pain · Spinal Fracture
30 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 13 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 stopped early · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
ReGenTree, LLC700 participants24 May 2019 to 7 Oct 2021
Dry Eye Syndromes · Dry Eye
ReGenTree, LLC601 participantsNov 2016 to Mar 2018
Dry Eye Syndrome
ReGenTree, LLC18 participants17 Sept 2015 to 9 Mar 2020
Neurotrophic Keratopathy
2 more mention it but do not test it. They only measure it or name it in their text.